<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385292</url>
  </required_header>
  <id_info>
    <org_study_id>OCUN-003</org_study_id>
    <nct_id>NCT02385292</nct_id>
  </id_info>
  <brief_title>Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation</brief_title>
  <official_title>Randomized, Controlled, Crossover, Multicenter Trial Comparing Quality of Tears Produced by Nasal Neurostimulation Versus Sham for Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculeve, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculeve, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
        -  To compare the change in levels of tear proteins and inflammatory mediators pre and post&#xD;
           administration between the intranasal and extranasal applications&#xD;
&#xD;
        -  To compare the goblet cell count following application between the intranasal and&#xD;
           extranasal applications&#xD;
&#xD;
        -  To compare fluorescein tear clearance with the application of the device intranasally&#xD;
           and extranasally applications&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, subjects will participate for three study days during up to a 44 day period,&#xD;
      consisting of a screening examination to determine eligibility on one day and study&#xD;
      applications on two different days. There are two applications, intranasal and extranasal.&#xD;
      Subjects will receive both applications, in random sequence, one at each of the two&#xD;
      application days (Visit 2 and Visit 3). The two applications consist of:&#xD;
&#xD;
        -  Active intranasal device application&#xD;
&#xD;
        -  Active extranasal device application&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2015</start_date>
  <completion_date type="Actual">March 31, 2016</completion_date>
  <primary_completion_date type="Actual">March 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorescein Tear Clearance With Application</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Level of Tear Proteins Pre and Post Administration</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Level of Inflammatory Mediators Pre and Post Administration</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Goblet Cell Count Following Application</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Intranasal then Extranasal Application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extranasal then Intranasal Application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oculeve Intranasal Lacrimal Neurostimulator</intervention_name>
    <description>The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.</description>
    <arm_group_label>Extranasal then Intranasal Application</arm_group_label>
    <arm_group_label>Intranasal then Extranasal Application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bilateral dry eyes&#xD;
&#xD;
          -  Capable of providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic or recurring epistaxis (nosebleeds)&#xD;
&#xD;
          -  Blood coagulation disorder&#xD;
&#xD;
          -  Uncontrolled or poorly controlled diabetes&#xD;
&#xD;
          -  Heart or pulmonary disease&#xD;
&#xD;
          -  Females who are pregnant, planning a pregnancy or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grutzmacher, Lewis &amp; Sierra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grutzmacher, Lewis &amp; Sierra</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Department of Ophthalmology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <results_first_submitted>September 22, 2021</results_first_submitted>
  <results_first_submitted_qc>September 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2021</results_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Then Extranasal Application</title>
          <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
        </group>
        <group group_id="P2">
          <title>Extranasal Then Intranasal Application</title>
          <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Then Extranasal Application</title>
          <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
        </group>
        <group group_id="B2">
          <title>Extranasal Then Intranasal Application</title>
          <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>participants</units>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fluorescein Tear Clearance With Application</title>
        <time_frame>Day 1</time_frame>
        <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Application</title>
            <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
          <group group_id="O2">
            <title>Extranasal Application</title>
            <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluorescein Tear Clearance With Application</title>
          <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Level of Tear Proteins Pre and Post Administration</title>
        <time_frame>Day 1</time_frame>
        <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Application</title>
            <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
          <group group_id="O2">
            <title>Extranasal Application</title>
            <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Tear Proteins Pre and Post Administration</title>
          <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Level of Inflammatory Mediators Pre and Post Administration</title>
        <time_frame>Day 1</time_frame>
        <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Application</title>
            <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
          <group group_id="O2">
            <title>Extranasal Application</title>
            <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Inflammatory Mediators Pre and Post Administration</title>
          <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Goblet Cell Count Following Application</title>
        <time_frame>Day 1</time_frame>
        <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Application</title>
            <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
          <group group_id="O2">
            <title>Extranasal Application</title>
            <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
          </group>
        </group_list>
        <measure>
          <title>Goblet Cell Count Following Application</title>
          <population>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Application</title>
          <description>Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
        </group>
        <group group_id="E2">
          <title>Extranasal Application</title>
          <description>Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator or other study-related personnel may not disclose to anyone or use any data, information, or materials related to this clinical trial without the express written consent of Oculeve.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>During transfer and acquisition of study record by sponsors, no study data has been located and all efforts to locate study data have been exhausted. Therefore, no study data is available to report at this time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

